



Announcement Summary

Entity name

TELEX PHARMACEUTICALS LIMITED

Date of this announcement

Thursday June 05, 2025

The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
New class - code to be confirmed	2024 Deferred Share Rights ex-US	7,966	30/05/2025
New class - code to be confirmed	2024 Deferred Share Rights US	10,342	30/05/2025
New class - code to be confirmed	2025 Performance Share Appreciation Rights US	2,881,250	30/05/2025

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

TELIX PHARMACEUTICALS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ACN

Registration number

616620369

1.3 ASX issuer code

TLX

1.4 The announcement is

New announcement

1.5 Date of this announcement

5/6/2025



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

does not have an existing ASX security code ("new class")



Part 3C - number and type of +securities the subject of this notification (new class)

ASX +security code

New class - code to be confirmed

+Security description

2024 Deferred Share Rights ex-US

+Security type

Other

ISIN code

Date the +securities the subject of this notification were issued

30/5/2025

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

Yes

Provide details of the KMP or +associates being issued +securities.

Name of KMP	Name of registered holder	Number of +securities
Darren Smith	Darren Smith	1,111
David Cade	David Cade	1,080

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.

Refer to Telix's Remuneration report, within its 2024 Annual Report accessible at <https://telixpharma.com/investor-centre/financial-reports-presentations/>

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Deferred Share Rights (2024 SRs) (allocation value: \$30.3922) granted to Telix employees as deferred equity component of 2024 Short Term Variable Remuneration (STVR) as part of Total Target Remuneration Package for 2024. Vesting is subject to continued service until after release of Telix's 2025 full year results in approximately February 2026, and with a two year exercise period following vesting. For further details refer to the Remuneration report in Telix's 2024 Annual Report accessible at <https://telixpharma.com/investor-centre/financial-reports-presentations/>

Any other information the entity wishes to provide about the +securities the subject of this notification

Issue details

Number of +securities

7,966

**ASX +security code**

New class - code to be confirmed

+Security description

2024 Deferred Share Rights US

+Security type

Other

ISIN code**Date the +securities the subject of this notification were issued**

30/5/2025

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

Yes

Provide details of the KMP or +associates being issued +securities.**Name of KMP****Name of registered holder****Number of +securities**

Darren Patti

Darren Patti

1,230

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.Refer to Telix's Remuneration report, within its 2024 Annual Report accessible at <https://telixpharma.com/investor-centre/financial-reports-presentations/>**Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms**Deferred Share Rights (2024 SRs) (allocation value: US\$21.7846) granted to Telix US domiciled employees as deferred equity component of 2024 Short Term Variable Remuneration (STVR) as part of Total Target Remuneration Package for 2024. Vesting and exercise is subject to continued service until after release of Telix's 2025 full year results in approximately February 2026. For further details refer to the Remuneration report in Telix's 2024 Annual Report accessible at <https://telixpharma.com/investor-centre/financial-reports-presentations/>**Any other information the entity wishes to provide about the +securities the subject of this notification**

Rights over Telix ordinary shares to be delivered as American Depositary Shares to US domiciled employees

Issue details

Number of +securities

10,342

ASX +security code

New class - code to be confirmed

+Security description

2025 Performance Share Appreciation Rights US

+Security type

Other

ISIN code



Date the +securities the subject of this notification were issued

30/5/2025

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

Yes

Provide details of the KMP or +associates being issued +securities.

Name of KMP	Name of registered holder	Number of +securities
Darren Patti	Darren Patti	95,958

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.

Refer to Telix's Remuneration report, within its 2024 Annual Report accessible at <https://telixpharma.com/investor-centre/financial-reports-presentations/>

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Performance Share Appreciation Rights (PSARs) (exercise price: US\$19.99) granted to Telix employees as 2025 Long Term Incentive. Vesting is subject to achievement of performance conditions and the terms of Telix's Equity Incentive Plan rules, with a measurement period of 2025-2027, and with a two year exercise period following vesting. For further details refer to the Remuneration report in Telix's 2024 Annual Report accessible at <https://telixpharma.com/investor-centre/financial-reports-presentations/>

Any other information the entity wishes to provide about the +securities the subject of this notification

Rights over Telix ordinary shares to be delivered as American Depositary Shares to US domiciled employees

Issue details

Number of +securities

2,881,250



Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)

ASX +security code and description	Total number of +securities on issue
TLX : ORDINARY FULLY PAID	338,109,048

4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
TLXAQ : SHARE RIGHTS EXPIRING 13-JUN-2027 EX NIL	80,000
TLXAR : PERFORMANCE RIGHTS	9,965,235
TLXAP : SHARE RIGHTS	1,455,000
TLXAO : SHARE APPRECIATION RIGHTS	14,223,198
TLXAT : CONVERTIBLE NOTES	3,250
TLXAM : OPTION EXPIRING 20-JUL-2026 EX \$5.37	304,992
TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL	100,000
TLXAL : OPTION EXPIRING 27-JAN-2026 EX \$4.38	330,437
TLXAS : PERFORMANCE SHARE INCENTIVE RIGHTS	440,000
New class - code to be confirmed : 2024 Deferred Share Rights ex-US	7,966
New class - code to be confirmed : 2024 Deferred Share Rights US	10,342
New class - code to be confirmed : 2025 Performance Share Appreciation Rights US	2,881,250



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

13